Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)

NCT02765854 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT02765854
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02765854 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2016
Completion date
May 23, 2023
Enrollment
70 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent plasma cell myeloma, refractory plasma cell myeloma